Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 5,64 M
EBIT 2016 -0,50 M
Net income 2016 -0,84 M
Debt 2016 -
Yield 2016 -
Sales 2017 6,59 M
EBIT 2017 -0,98 M
Net income 2017 -0,83 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 9,56x
Capi. / Sales2017 8,18x
Capitalization 53,9 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
03/14Earnings Release
More about the company
Surperformance© ratings of IntelGenx Technologies Cor
Trading Rating : - Investor Rating :
More Ratings
Latest news on INTELGENX TECHNOLOGIES COR
01/19 INTELGENX TECHNOLOGIES : Grants Stock Options
01/19 INTELGENX TECHNOLOGIES : Grants Stock Options
01/04 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
01/04 INTELGENX TECHNOLOGIES : Announces Definitive Agreement with Chemo Group for a G..
2016 INTELGENX TECHNOLOGIES CORP. (OTCMKT : IGXT) Files An 8-K Other Events
2016 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
2016 INTELGENX TECHNOLOGIES : Announces Development and Commercialization Agreement w..
2016 INTELGENX TECHNOLOGIES : Announces Development and Commercialization Agreement w..
2016 INTELGENX TECHNOLOGIES CORP. (OTCMKT : IGXT) Files An 8-K Other Events
2016 INTELGENX TECHNOLOGIES CORP. : Other Events (form 8-K)
More news
Sector news : Generic Pharmaceuticals
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Generic Pharmaceuticals
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 80%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin Chief Financial Officer & Executive Vice President
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
John Archibald Troup Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
INTELGENX TECHNOLOGIES..54
OTSUKA HOLDINGS CO LTD5.93%26 246
SUN PHARMACEUTICAL IND..2.02%22 619
ONO PHARMACEUTICAL CO...-9.03%11 960
ASPEN PHARMACARE HOLDI..6.53%10 151
SHANGHAI FOSUN PHARMAC..7.43%8 621
More Results